ATAI News and Press, ATAI Life Sciences N.V. From 07/07/21

BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and p...

Palm Beach, FL – July 7, 2021 – Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychede...

Mental illnesses are tough to treat, and modern medicine can't guarantee relief for many patients. New therapies derived from psychedelic compounds, however, are offering hope, not to mention a slew of opportunities for forward-thinking investors. Since ATAI Life Sciences' (NASDAQ...

NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...

Mushrooms seem to be popping up everywhere these days. All as millions digest the idea that mushrooms can support immune systems, reduce inflammation, and help improve moods. Chaga for example has even caught the attention to coffee drinkers, says Thrillist. " It's a superfood said to preve...

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance International IPO Index was down 3.4% year-to-date, while the ACWX was up 10.4%. For f...

MBPROJEKT_Maciej_Bledowski/iStock via Getty Images Advanced technology and cryptocurrencies might steal most of the spotlight on Wall Street, but a very old company had a very good day on Friday. Gunmaker Smith & Wesson (SWBI) rallied on news of a strong earnings report. Elsewhere, Sykes ...

Christian Angermayer, founder of atai Life Sciences (ATAI), said the firm's IPO will allow the firm to push its products through clinical trials, as it looks to create therapies based on psychedelic drugs like magic mushrooms and ayahuasca. This comes as the Peter Thiel-backed psychedelic psy...

Atai Life Sciences  (Nasdaq: ATAI)  announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. atai’s common shares are expected to begin trading on the Nasdaq Global ...

Psychedelic industry leader Atai Life Sciences B.V. (Nasdaq: ATAI)  announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. atai’s common shares are expected to begin tradin...